Johannes J. P. Kastelein
Founder at NewAmsterdam Pharma BV
Profile
Johannes J.
P.
Kastelein is the founder of Xenon Pharmaceuticals, Inc. (1996), Amsterdam Molecular Therapeutics (AMT) Holding NV (1998), and NewAmsterdam Pharma BV (2019) where he holds the title of Executive Director & Chief Scientific Officer.
He is currently the Director of Dutch Atherosclerosis Society, a Professor at Academic Medical Center and the University of Amsterdam, and a Member of the International Atherosclerosis Society and European Atherosclerosis Society.
In the past, he served as an Independent Director at VIVUS, Inc. (2013-2015) and as a Director at Symphony Genisis, Inc.
Johannes J. P. Kastelein active positions
Companies | Position | Start |
---|---|---|
International Atherosclerosis Society
International Atherosclerosis Society Miscellaneous Commercial ServicesCommercial Services The International Atherosclerosis Society is based in Houston, TX. The private company's focus and description are not provided in the given dictionary. | Corporate Officer/Principal | - |
University of Amsterdam | Corporate Officer/Principal | - |
NewAmsterdam Pharma BV
NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Founder | 01/01/2019 |
Academic Medical Center
Academic Medical Center Hospital/Nursing ManagementHealth Services Academic Medical Center operates a medical center and a medical research facility. It also provides education and training. The company was founded in 1983 and is headquartered in Amsterdam, the Netherlands. | Corporate Officer/Principal | - |
European Atherosclerosis Society | Corporate Officer/Principal | - |
Dutch Atherosclerosis Society | Director/Board Member | - |
Former positions of Johannes J. P. Kastelein
Companies | Position | End |
---|---|---|
VIVUS, INC. | Director/Board Member | 03/03/2015 |
XENON PHARMACEUTICALS INC. | Founder | - |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Founder | - |
░░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
XENON PHARMACEUTICALS INC. | Health Technology |
Private companies | 8 |
---|---|
VIVUS, Inc.
VIVUS, Inc. Pharmaceuticals: MajorHealth Technology VIVUS, Inc. engaged in the development and commercialization of novel therapeutic products. The firm’s products were indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and it was headquartered in Campbell, CA. | Health Technology |
Academic Medical Center
Academic Medical Center Hospital/Nursing ManagementHealth Services Academic Medical Center operates a medical center and a medical research facility. It also provides education and training. The company was founded in 1983 and is headquartered in Amsterdam, the Netherlands. | Health Services |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Commercial Services |
Symphony Genisis, Inc.
Symphony Genisis, Inc. Pharmaceuticals: MajorHealth Technology Symphony GenIsis, Inc. manufactures biopharmaceutical drugs. It develops and researches on cholesterol-lowering drug, ISIS 301012 and two novel diabetes drugs from its metabolic diseases program. The company is located in Rockville, MD | Health Technology |
International Atherosclerosis Society
International Atherosclerosis Society Miscellaneous Commercial ServicesCommercial Services The International Atherosclerosis Society is based in Houston, TX. The private company's focus and description are not provided in the given dictionary. | Commercial Services |
European Atherosclerosis Society | |
Dutch Atherosclerosis Society | |
NewAmsterdam Pharma BV
NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Health Technology |
- Stock Market
- Insiders
- Johannes J. P. Kastelein